Date: Wednesday, October 18
Time: 13:30 – 14:45
Session Hall 2, Willem Burger Zaal
Exploring advancements in the T1D treatment landscape: Is there a future for disease-modifying therapies?
| 13:30 – 13:35 | Welcome and objectives | Chair: Chantal Mathieu |
| 13:35 – 13:50 | A shifting paradigm: The current treatment landscape and unmet needs in T1D | Lucienne Chatenoud |
| 13:50 – 14:05 | Emerging disease-modifying therapies in T1D: Findings from clinical research | Colin Dayan |
| 14:05 – 14:20 | Potential treatments for altering the course of T1D | Kevan Herold |
| 14:20 – 14:30 | Evolving T1D landscape: Potential clinical implications | Chantal Mathieu |
| 14:30 – 14:45 | Is there a future for disease-modifying therapies? A panel discussion | All |
Date: Wednesday, October 18
Time: 13:30 – 14:45
Workshop Room, Van Weelde Zaal
Pediatric Care Strategies: A Practical Approach to Implementing the Latest Guidelines & Utilizing Tubeless Pump Therapy in a Case-Based Workshop
| Updates on the Global Omnipod® 5 Launch, Clinical Studies & Innovations at Insulet | Dr. Trang Ly |
| Omnipod DASH® in Clinical Practice | Dr. Marc de Kerdanet |
| Omnipod® 5 in Clinical Practice | Cari Berget, MPH, RN, CDCES |
Date: Thursday, October 19
Time: 13:15 – 14:30
Session Hall 3, Jurriaanse Zaal
A Pediatric Perspective: Navigating the World of Automated Insulin Delivery
Speaker:
Greg Forlenza, MD, Pediatric Endocrinology, University of Colorado Hospital, Children’s Hospital Colorado (USA)
Torben Biester, MD, Pediatric Diabetologist & Emergency Physician (Germany)
Chair:
Inge Gies, MD, Head of Pediatric Department, Pediatric Endocrinologist & Diabetologist, UZ Brussel (Brussels)
Program:
In the rapidly evolving landscape of pediatric diabetes care, continuous glucose monitoring (CGM) systems and Automated Insulin Delivery (AID) have emerged as game-changers. This comprehensive presentation is a deep dive on the latest clinical evidence, guidelines, and real-world outcomes surrounding these technologies. Attendees will gain insights from the NICE Guidelines regarding CGM’s role in pediatric diabetes. The session emphasizes the benefits of early CGM initiation and presents real-world results from systems like OP5 and Control-IQ. Highlights include the Beta Bionics pivotal trial findings and an introduction to the innovative Dexcom G7 system. Practical strategies for integrating these technologies into clinical practice will be discussed, followed by a comparison of major AID systems and solutions to common concerns. Through this presentation, medical professionals will be better equipped to navigate the rapidly evolving landscape of pediatric diabetes management.
Date: Thursday, October 19
Time: 13:15 – 14:30
Workshop Room, Van Weelde Zaal
Experiencing the potential of the MiniMed™ 780G system in the young with type 1 diabetes
Chair: Jen McVean & Henk-Jan Aanstoot
| The MiniMed™ 780G system in the pediatric population: how does it work | Dr. Jen McVean (USA) |
| Early adoption after diagnosis of type 1 diabetes with the MiniMed™ 780G system | Dr. Ivana Rabbone (IT) |
| Striking the balance: navigating interactions withMiniMed™ 780G system | Dr Henk-Jan Aanstoot (NL) |
| Question & Answers | |
Date: Thursday, October 19
Time: 17:15 – 18:45
Session Hall 2, Willem Burger Zaal
Evening Symposium – The Now Known: Disrupting the pathogenesis of T1D
| 17:15 – 17:20 | Welcome and objectives | Thomas Danne |
| 17:20 – 17:35 | Describing the Now Known of T1D pathogenesis | Thomas Danne |
| 17:35 – 17:50 | General population screening for T1D: Experience from Sweden | Daniel Agardh |
| 17:50 – 18:00 | In conversation
Conversation between the first two speakers about how different disciplines can work together to monitor and diagnose T1D at an early stage |
Daniel Agardh
and Thomas Danne |
| 18:00 – 18:15 | Towards the future: Creating space to prepare for changing directions in T1D management | Sanjoy Dutta |
| 18:15 – 18:30 | Future directions in T1D management: Disrupting disease pathogenesis | Kimber Simmons |
| 18:30 – 18:45 | In conversation
Conversation between the second two speakers about how different disciplines can work together to help individuals and their families prepare for and potentially delay T1D Full panel discussion and audience Q&A |
Sanjoy Dutta
and Kimber Simmons Full panel for Q&A |
Date: Friday, October 20
Time: 08:00 – 09:00
Workshop Room, Van Weelde Zaal
Automated insulin delivery with mylife CamAPS FX to manage type 1 diabetes in childhood and adolescence: practical insights
Program & Speakers:
Addressing the unmet needs to manage type 1 diabetes in children and adolescents
Dr Julia Ware, Clinical Research Fellow & Paediatric Registrar, Department of Paediatrics, University of Cambridge, Cambridge, UK
Management of challenging situations with mylife CamAPS FX system AID system
Dr Martin Tauschmann, PhD, Medical University of Vienna, Dept. of Pediatrics, Vienna, Austria
Dr Julia Ware, Clinical Research Fellow & Paediatric Registrar, Department of Paediatrics, University of Cambridge, Cambridge, UK
Date: Friday, October 20
Time: 13:30 – 14:45
Session Hall 3, Jurriaanse Zaal
Establishing the role of the MiniMed™ 780G system in the pediatric population with type 1 diabetes
Chair: Jen McVean & Henk-Jan Aanstoot
| Introduction | Dr. Jen McVean (USA) |
| Real-world consistent performance of the MiniMed™ 780G system in the pediatric age | Prof. Ohad Cohen (IL) |
| Bringing technology to the treatment of type 1 diabetes: the Diabetes therapy approach | Dr. Henk-Jan Aanstoot (NL) |
| Simplifying meal management with the MiniMed™ 780G system in the young with type 1 diabetes | Prof. Goran Petrovski (Q) |
| Simplifying diabetes management outside of home for children with type 1 diabetes and their parents | Dr. Simone von Sengbusch |
| Questions & Answers | |
